More iron in fewer infusions.
Only Injectafer provides up to 1500 mg of iron in just two
administrations of up to 750 mg, separated by at least 7 days*
INDICATIONS
Administration Options†
Injectafer (ferric carboxymaltose injection) is an iron
replacement product indicated for the treatment of
iron deciency anemia (IDA) in adult patients
• who have intolerance to oral iron or have had
unsatisfactory response to oral iron
• who have non-dialysis dependent chronic kidney disease
• IV infusion over at least 15 minutes
• Slow IV push over at least 7.5 minutes
Monitor patients during and after Injectafer administration
for at least 30 minutes and until clinically stable following
completion of the infusion.
* For adult patients weighing 50 kg (110 lb) or more, give each dose as 750 mg. For patients weighing less than 50 kg (110 lb), give each dose as
15 mg/kg body weight.
† When administered via IV infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that
the concentration of the infusion is not <2 mg of iron per mL and administer over at least 15 minutes. When administered as a slow IV push, give
at the rate of approximately 100 mg (2 mL) per minute.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Injectafer is contraindicated in patients with hypersensitivity to
Injectafer or any of its inactive components.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylactic-type
reactions, some of which have been life-threatening and fatal, have
been reported in patients receiving Injectafer. Patients may present
with shock, clinically significant hypotension, loss of consciousness,
and/or collapse. Monitor patients for signs and symptoms of
hypersensitivity during and after Injectafer administration for at
least 30 minutes and until clinically stable following completion
of the infusion. Only administer Injectafer when personnel and
therapies are immediately available for the treatment of serious
hypersensitivity reactions. In clinical trials, serious anaphylactic/
anaphylactoid reactions were reported in 0.1% (2/1775) of subjects
receiving Injectafer. Other serious or severe adverse reactions
potentially associated with hypersensitivity which included, but were
not limited to, pruritus, rash, urticaria, wheezing, or hypotension were
reported in 1.5% (26/1775) of these subjects.
In clinical studies, hypertension was reported in 3.8% (67/1775) of
subjects. Transient elevations in systolic blood pressure, sometimes
occurring with facial flushing, dizziness, or nausea were observed
in 6% (106/1775) of subjects. These elevations generally occurred
immediately af